NCT04158739 Flotetuzumab for the Treatment of Pediatric Recurrent or Refractory Acute Myeloid Leukemia Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT04115631 A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT04113616 An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML) Status TERMINATED Phase PHASE1/PHASE2
NCT04112589 A Clinical Trial to Assess the Efficacy and Safety of the Combination of a Drug Call Quizartinib With Chemotherapy (FLAG-IDA) in Patients With Acute Myeloid Leukemia That Has Not Responded to the First Treatment or That Has Returned After the First Treatment Status UNKNOWN Phase PHASE1/PHASE2
NCT04107727 Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML) Status COMPLETED Phase PHASE2
NCT04100330 A Study of Ficlatuzumab With HiDAC and HiDAC Alone in Adults With Relapsed or Refractory Acute Myeloid Leukemia Status WITHDRAWN Phase PHASE2
NCT04061239 Comparison of Therapies Before Stem Cell Transplantation in Patients With Higher Risk MDS and Oligoblastic AML Status RECRUITING Phase PHASE2
NCT04047641 Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Status RECRUITING Phase PHASE1/PHASE2
NCT04043494 International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma Status RECRUITING Phase PHASE3
NCT04029688 A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors Status TERMINATED Phase PHASE1/PHASE2
NCT03983824 Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT03964090 Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS) Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT03962465 Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Patients With Relapsed/Refractory B-cell ALL Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT03959085 Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy Status RECRUITING Phase PHASE3
NCT03926624 Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage Status TERMINATED Phase PHASE3
NCT03914625 A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT03913559 Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia Status TERMINATED Phase PHASE2
NCT03900949 Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia Status COMPLETED Phase PHASE1